Research

With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.

LATEST NEWS

  • August 10, 2017First Human Application of Novel PET Tracer for Prostate Cancer
    In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine, for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
  • August 10, 2017First Human Application of Novel PET Tracer for Prostate Cancer
    In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine, for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
  • August 7, 2017First Human Application of Novel PET Tracer for Prostate Cancer
    In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
  • August 3, 2017SNMMI publishes appropriate use criteria for hepatobiliary scintigraphy in abdominal pain
    The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for hepatobiliary scintigraphy in abdominal pain. This is the third in a series of new AUC developed by SNMMI in its role as a qualified provider-led entity (PLE) under the Medicare Appropriate Use Criteria Program for Advanced Diagnostic Imaging.
  • August 3, 2017SNMMI Publishes Appropriate Use Criteria for Hepatobiliary Scintigraphy in Abdominal Pain
    SNMMI has published appropriate use criteria (AUC) for hepatobiliary scintigraphy in abdominal pain. This is the third in a series of new AUC developed by SNMMI in its role as a qualified provider-led entity (PLE) under the Medicare Appropriate Use Criteria Program for Advanced Diagnostic Imaging. The other recently released AUC are for bone scintigraphy in prostate and breast cancer and for ventilation/perfusion (V/Q) imaging in pulmonary embolism.
  • August 1, 2017New Imaging Tracer Allows Early Assessment of Abdominal Aortic Aneurysm Risk
    Yale University researchers have developed a way in which medical imaging could potentially be used to assess a patient’s rupture risk for abdominal aortic aneurysm. Delaying surgical treatment can be life-threatening, and this new type of imaging could allow physicians to diagnose disease and better plan its management. The study is presented in the featured article of the August issue of The Journal of Nuclear Medicine.
  • August 1, 2017New Imaging Tracer Allows Early Assessment of Abdominal Aortic Aneurysm Risk
    Yale University researchers have developed a way in which medical imaging could potentially be used to assess a patient's rupture risk for abdominal aortic aneurysm. Delaying surgical treatment can be life-threatening, and this new type of imaging could allow physicians to diagnose disease and better plan its management. The study is presented in the featured article of the August issue of The Journal of Nuclear Medicine.
  • July 20, 2017Neuroendocrine Tumor Research Foundation Grant Opportunities
    NETRF is requesting applications for a new round of scientific and clinical research grants for advancing the treatment of and search for cures to neuroendocrine tumors (NETs). The grants, which will take effect in 2018, vary from $50,000 to $1.2 million and fall into three categories: accelerator grants, investigator grants, and pilot project grants. Some are available for as many as four years.

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities.  Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.